NAA-FOFOI WHARTON: Open Payments
NPI 1639792088 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,086 in 87 payments from 16 companies in 2025. Trend: 2023 $1,188 · 2024 $2,101 · 2025 $3,086
Food & beverage: $3,002Education: $84
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company | 28 | $1,040 |
| Gilead Sciences, Inc. | 7 | $433 |
| ABBVIE INC. | 12 | $348 |
| Lilly USA, LLC | 6 | $207 |
| AstraZeneca Pharmaceuticals LP | 4 | $196 |
| Merck Sharp & Dohme LLC | 7 | $143 |
| Braeburn Inc. | 2 | $130 |
| EMD Serono, Inc. | 2 | $127 |
| Neurocrine BioSciences, Inc. | 3 | $95 |
| Hologic Sales and Service, LLC | 3 | $81 |
Products named: DOVATO, CABENUVA, MAVYRET, MOUNJARO, TEZSPIRE, Veklury, BRIXADI, Serostim.
Industry payments across PA — which companies pay providers there.
